NCT00004431已完成不适用
Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
OBJECTIVES: I. Evaluate the efficacy of L-baclofen in patients with refractory trigeminal neuralgia.
II. Evaluate the safety and tolerance of L-baclofen in these patients.
详细描述
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, parallel study.
Patients are randomized to receive either L-baclofen or placebo orally at increasing daily doses for 1 week. Patients then continue to receive the maximum dosage acceptable for a 1 week maintenance period.
Patients, thereafter, may enroll in a long term open label study with L-baclofen.
Patients are followed at 1, 3, 6, 9, and 12 months.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics-- Idiopathic trigeminal neuralgia - Paroxysmal attacks of facial or frontal pain lasting a few seconds to less than 2 minutes - Pain has at least 4 of the following characteristics: Distribution along one or more divisions of the trigeminal nerve Sudden, intense, sharp, superficial, stabbing, or burning quality Pain intensity severe Precipitation from trigger areas, or by certain daily activities such as eating, talking, washing the face, or cleaning the teeth Between paroxysms entirely asymptomatic - No neurological deficit - Attacks are stereotyped in the individual patient - Exclusion of other causes of facial pain by history, physical examination and special investigations when necessary Must be uncontrolled or refractory as defined by occurrence of at least 2 paroxysms of pain per day despite conventional treatment with maximally tolerated doses of carbamazepine --Prior/Concurrent Therapy-- No concurrent medication for trigeminal neuralgia other than carbamazepine, phenytoin, and neurontin Concurrent medication for other conditions allowed Concurrent medication must be on stable dose(s) --Patient Characteristics-- Hepatic: No significant hepatic disease Renal: No significant renal disease Neurological: No evidence of progressing neurological disorder (e.g., intracranial neoplasm, multiple sclerosis) Other: No history of drug abuse Not pregnant Effective contraception required of all fertile patients
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in FranceAlcohol DrinkingAlcohol WithdrawalCirrhosisNCT02835365Centre Hospitalier Intercommunal Creteil218
已完成
3 期
Dutch National ITB Study in Children With Cerebral PalsySpasticityCerebral PalsyNCT00367068Maastricht University18
撤回
不适用
Open Label Treatment of Severe Tactile Defensiveness With Intrathecal BaclofenAutism Spectrum DisorderNCT01352611University of Missouri-Columbia
进行中（未招募）
不适用
A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI responseGastroesophageal reflux diseaseEUCTR2009-017351-96-BEZleuven
进行中（未招募）
1 期
Study investigating the effect of baclofen in patients with postprandial regurgitation or belchingMedDRA version: 14.0Level: LLTClassification code 10004222Term: BelchingSystem Organ Class: 10017947 - Gastrointestinal disordersRumination syndrome and supragastric belchingMedDRA version: 14.0Level: LLTClassification code 10039292Term: Rumination disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002745-35-BEZLeuven20